Myovant Sciences Ltd.
MYOVDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Estradiol/norethindrone acetate
Heavy Menstrual Bleeding
Relugolix
Endometriosis Related Pain
Leuprolide Acetate
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Estradiol/norethindrone acetate | Phase 3 | Heavy Menstrual Bleeding | - | - |
Relugolix | Phase 3 | Endometriosis Related Pain | - | - |
Leuprolide Acetate | Phase 3 | Prostate Cancer | - | - |
Frequently asked questions
What is in Myovant Sciences Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Myovant Sciences Ltd.'s (MYOV) pipeline across Phase 3. Its lead program is Estradiol/norethindrone acetate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Myovant Sciences Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Myovant Sciences Ltd. (MYOV) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MYOV biotech catalysts?→
Add MYOV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Myovant Sciences Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.